Case-Based Roundtable
General Dermatology
Eczema
Chronic Hand Eczema
Alopecia
Aesthetics
Vitiligo
COVID-19
Actinic Keratosis
Precision Medicine and Biologics
Rare Disease
Wound Care
Rosacea
Psoriasis
Psoriatic Arthritis
Atopic Dermatitis
Melasma
NP and PA
Skin Cancer
Hidradenitis Suppurativa
Drug Watch
Pigmentary Disorders
Acne
Pediatric Dermatology
Practice Management
Prurigo Nodularis
Buy-and-Bill

The Evolution of Topical PDE4 Inhibitors in Treating Atopic Dermatitis : Episode 4

Opinion

Video

November 15, 2024

Roflumilast: Mechanism, and Use for Proactive AD Management

Author(s):

Lisa Swanson, MD, FAAD,Benjamin Lockshin, MD, FAAD

Key Takeaways

PDE4 inhibitors vary in selectivity, binding affinity, and pharmacokinetics, affecting therapeutic outcomes and adverse effects.
Differences in isoform selectivity and tissue distribution influence efficacy and safety profiles of PDE4 inhibitors.
Understanding these distinctions is crucial for optimizing treatment strategies and minimizing side effects.

Panelists discuss common misconceptions about the mechanism of action of PDE4 inhibitors in clinical practice, emphasizing that not all PDE4 inhibitors are created equal and how these differences can significantly impact their efficacy and safety profiles.

EP: 1.Evolution of Topical Treatment for AD

EP: 2.PDE4 Inhibitor Roflumilast for AD

EP: 3.Comparing the Efficacy of Roflumilast and Crisaborole

Now Viewing

EP: 4.Roflumilast: Mechanism, and Use for Proactive AD Management

EP: 5.Considerations for Using Roflumilast in the Pediatric Population, and for Skin of Color

EP: 6.Patient Education and Novel Topical Therapies for AD

EP: 7.Pediatric and Adult AD Cases Illuminate Benefits of Topical PDE4 Inhibitors

What are some common misconceptions about the mechanism of PDE4 inhibitors that you encounter in clinical practice?
1. Please explain why all PDE4 inhibitors are not created equal. How might these differences impact efficacy and safety profile?